Life Biosciences has received FDA clearance to begin a first-in-human Phase 1 clinical trial of ER-100, a gene therapy ...

A team linked to Harvard Medical School has dosed the first patient in a clinical trial designed to reverse cellular aging in ...

Blindness itself might become, at least in certain cases, partially reversible. This potential future stems from one of the ...

Arc Institute, Gladstone Institutes, and University of California, San Francisco, scientists have developed an epigenetic editing platform that enables safe modification of multiple genes in primary ...

Cellular reprogramming is the hottest topic in longevity science, with tech titans like Sam Altman investing in it. It's now being tested in humans.

The outspoken longevity scientist David Sinclair has been predicting that one day, you’ll go to the doctor and get a prescription that will make you 10 years younger. Now MIT Technology Review has ...

Lactate, once considered a metabolic waste product, is now recognized as a key regulator of cellular homeostasis and disease progression. In gynecological malignancies-including ovarian, cervical, and ...

Armed with a fully subscribed $80 million series D round, Life Biosciences Inc. is making progress with its lead candidate, ER-100, which is in phase I trials testing its theory on reversing the ...

People with obesity and type 2 diabetes are at high risk of blood vessel damage. This risk depends not only on the genes a person carries, but also on how they are "read." By changing the epigenetic ...